ImmunoGen, Inc. (IMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.80+0.12 (+2.11%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 5.68 |
| Open | 5.73 |
| Bid | 5.80 x 3000 |
| Ask | 6.20 x 4000 |
| Day's Range | 5.57 - 5.99 |
| 52 Week Range | 3.43 - 10.88 |
| Volume | 5,007,680 |
| Avg. Volume | 1,417,347 |
| Market Cap | 1.16B |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.27 |
| Earnings Date | Nov 04, 2021 - Nov 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.79 |
- Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., August 02, 2021--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zacks
ImmunoGen (IMGN) Q2 Loss Narrower Than Expected, Revenues Lag
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates.
- Motley Fool
ImmunoGen, inc (IMGN) Q2 2021 Earnings Call Transcript
At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our CFO.
© 2021 Verizon Media. All rights reserved.
